Loading
NASDAQHealthcareBiotechnology
Latest quote
$11.26
−$0.05 · -0.44%
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Latest quote
$11.26
−$0.05 · -0.44%
After-hours
$11.23
−$0.03 · -0.27%
Oct 8, 7:25 PM ET
Regular session · ET · Market data may be delayed.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Day range
Current $11.26
52-week range
Current $11.26
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
68
Bullish
Risk
61
High Risk
Momentum
72
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Day range
Current $11.26
52-week range
Current $11.26
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 1M USD | 7.6M USD |
| Cost of goods sold | — | — | — | 100K USD | 200K USD |
| Gross profit | — | — | — | 900K USD | 7.4M USD |
| Research and development | 16.02M USD | 19.1M USD | 24.01M USD | 30.27M USD | 21.37M USD |
| Selling, general, and administrative | 12.25M USD | 12.42M USD | 13.86M USD | 12.58M USD | 11.32M USD |
| Operating expenses | 28.27M USD | 31.51M USD | 37.87M USD | 42.85M USD | 32.69M USD |
| Interest income | 1.41M USD | 632K USD | 525K USD | 317K USD | 6K USD |
| Depreciation and amortization | — | 31.51M USD | 37.87M USD | 457K USD | 1.27M USD |
| Operating income | −28.27M USD | −31.51M USD | −37.87M USD | −41.95M USD | −25.29M USD |
| Net income | −26.86M USD | −30.88M USD | −37.34M USD | −41.3M USD | −20.7M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 8, 2019 | 1:50 | — | — |
Stock split | Jan 2, 2018 | 1:30 | — | — |
Stock split | Nov 14, 2016 | 1:20 | — | — |
Effective Nov 8, 2019
1:50
Effective Jan 2, 2018
1:30
Effective Nov 14, 2016
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI65.86M0.65%10.08B USD0.35%$149.29-0.63%
iShares Russell 2000 ETFIWM59.82M0.08%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF28.86M0.03%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO21.26M0.15%14.25B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO14.47M0.08%18B USD0.06%$112.1-0.10%
Schwab U.S. Small-Cap ETFSCHA12.04M0.06%21.7B USD0.03%$32.66+0.15%
Vanguard Health Care ETFVHT8.01M0.04%22B USD0.09%$313.85-0.46%
iShares Micro-Cap ETFIWC7.16M0.54%1.33B USD0.60%$182.79-0.31%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
